Technology to Diagnose the Risk of Post-operative Recurrence of Early-Stage Cancer, Sysmex

Tokyo (JCNN) - Sysmex Corporation (TSE: 6869) has announced the development of a new technology based on a cell cycle profiling (C2P) for diagnosis of the risk of recurrence in patients with early-stage cancer... click link for more info.

Continue to Technology to Diagnose the Risk of Post-operative Recurrence of Early-Stage Cancer, Sysmex on Medical News Today.

Medical Buzz delivers the most recent headlines from the medical world. Diseases, cures, accidents, medicin. Click below for more headlines ...
Medical buzz